NCI Cancer Bulletin: Testing Dose-Dense Paclitaxel (Taxol) for Ovarian and Related Cancers - GOG-0262

"....Further bolstering evidence of dose-dense paclitaxel’s promise in ovarian cancer, the Japanese GOG conducted a phase III randomized clinical trial and showed that women receiving dose-dense therapy experienced statistically significantly longer progression-free survival and were more likely to be alive after 2 years....."

“Data from phase II studies show that dose-dense paclitaxel has activity in highly resistant ovarian cancer,” said Dr. Chan. “And the Japanese study has produced promising data, but there are differences in the prevailing ovarian cancer cell types, and possibly the genomic and toxicity profiles, of ovarian cancer in Asian compared with Western women. As such, these results need to be confirmed in other ethnicities before the dose-dense regimen can be considered the new standard of care.”

For More Information

See the lists of entry criteria and trial contact information or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The toll-free call is confidential.

IMEDEX: Interactive Case: Ovarian Cancer: Front-Line Therapy in Patient with Inadequate Debulking Surgery

Note:  registration required (free), discusses Japanese trial with weekly Taxol and increased overall survival, GOG 262 ((see arms 1 & 2)  etc...

Interactive Case: Ovarian Cancer: Front-Line Therapy in Patient with Inadequate Debulking Surgery VIEW ACTIVITY Overview: Dr Bradley Monk very eloquently describes a case of newly diagnosed advanced ovarian cancer and reinforces the importance of debulking surgery and combination chemotherapy. Various therapeutic options and recent clinical trial data are discussed. Topics: • Small and large volume residual disease and treatment decision making • Standards and clinical trials • Role of antiangiogenic agents in ovarian cancer management

abstract: Clinical features of 215 stage I ovarian tumors in Japanese women (borderline vs stage 1 clear cell; stage1C)

PURPOSE: Differences of the clinical features of Stage I borderline ovarian tumors and Stage I ovarian cancer need to be clarified.
METHODS: We retrospectively investigated 215 patients with Stage I ovarian tumors (67 with borderline tumors and 148 with ovarian cancer) treated between 1988 and 2001.
RESULTS: Only one patient with a borderline tumor developed recurrence, while recurrence was found in 20 patients with Stage I ovarian cancer. There was a significant difference in the recurrence rate between patients with Stage Ia or Ib ovarian cancer and those with Stage Ic cancer (p = 0.007). Clear cell adenocarcinoma showed a higher recurrence rate. Among our patients with recurrence, only five in whom the recurrent tumor could be surgically resected are currently alive and disease-free.
CONCLUSIONS: This study confirmed the low aggressiveness of Stage I borderline ovarian tumors and high aggressiveness of Stage Ic ovarian cancer or clear cell adenocarcinoma. In patients with recurrence, surgical resection may improve survival.

PMID: 20882880 [PubMed - in process]